Hormone replacement therapy and cardiovascular risk in post-menopausal women with NIDDM

Diabetic Medicine

Volumn 13, Issue 9, 1996, Pages 782-788

  Sattar, N ^a,b   Jaap, A J ^a   MacCuish, A C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Coronary heart disease; Hormone replacement therapy; NIDDM

Indexed keywords

CORONARY RISK; DYSLIPIDEMIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; POSTMENOPAUSE; REVIEW; RISK FACTOR;

BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; POSTMENOPAUSE; PREVALENCE; RISK FACTORS; THROMBOSIS;

EID: 0029818569     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199609)13:9<782::AID-DIA177>3.0.CO;2-I     Document Type: Review

References (88)

1. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham study. Am Heart J 1985; 110: 1100-1107.
2. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br Med J 1993; 406: 1313-1318.
3. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984; 26: 489-496.
4. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, et al. Estrogen replacement and coronary heart disease. Effect on survival in post-menopausal women. Arch Intern Med 1990; 150: 2557-2562.
5. Hong MK, Romm PA, Reagen K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992; 70: 1637-1638.
6. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. N Engl J Med 1993; 328: 1069-1075.
7. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Eithell H, et al. The risk of myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obs Gyn 1992; 99: 821-828.
8. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of oestrogens and progestens and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.
9. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
10. Luotola H, Pyorala T, Loikkanen M. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas 1986; 8: 245-253.
11. Barrett-Connor E, Laasko M. Ischaemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531-534.
12. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. J Am Med Assoc 1995; 273: 199-208.
13. Brussard HE, Gevers Leuven JA, Kluft C, Krans HMJ. Oestrogen replacement improves insulin response, lipoproteins and fibrinolysis in women with NIDDM (Abstract). Diabetologia 1995; 38: A25.
14. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Drugs 1994; 47 (suppl 2): 35-41.
15. Bailey CJ, Ahmed-Sorour H. Role of ovarian hormones in the long-term control of glucose homeostasis: the effects on insulin secretion. Diabetologia 1980; 19: 475-481.
16. Shi K, Mizuno A, Sano T, Ishida K, Shima K. Sexual differences in the incidence of diabetes mellitus in Otsuka-Long-Evans-Tokoshima-Fatty rats: effects of castration and sex-hormone replacement on its incidence. Metabolism 1994; 43: 1214-1220.
17. Björntorp B. Fatty acids, hyperinsulinaemia, and insulin resistance: which comes first? Curr Opin Lipidol 1994; 5: 166-174.
18. Knudsen P, Eriksson J, Lahdenperä S, Kahri J, Groop L, Taskinen M-R and the Botnia Study Group. Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia 1995; 38: 344-350.
19. Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984; 311: 953-959.
20. Tall AR. Plasma lipid transfer proteins. J Lipid Res 1986; 27: 361-367.
21. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-253.
22. Jacobs DR, Meban IL, Bangiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47.
23. Steiner C. The dyslipoproteinaemia of diabetes. Atherosclerosis 1994; 110 (suppl): 527-533.
24. Nielsen FS, Voldsguard AI, Gall M-A, Rossing P, Hommel E, Anderson P, et al. Apolipoprotein (a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 1993; 36: 438-444.
25. Davies M, Rayman G, Day J. Increased incidence of coronary disease in people with impaired glucose tolerance: link with increased lipoprotein (a) concentrations? Br Med J 1992; 304: 1610-1611.
26. Tan CE, Forster L, Caslake MJ, Bedford D, Watson TDG, McConnell M, et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipaemic men and women. Arterioscler Thromb Vasc Biol 1995; 15: 1839-1848.
27. Tikkanen MJ, Nikkilä EA. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 1987; 113: 562-567.
28. Baynes C, Henderson AD, Anyaoku V, Richmond W, Hughes CL, Johnston DG, et al. The role of insulin sensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Diabetic Med 1991; 8: 560-566.
29. Walsh BW, Schiff I, Rosner, Greenberg L, Ranvikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.
30. Walsh BW, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal oestrogen on HDL metabolism. J Lipid Res 1994; 35: 2083-2093.
31. Knopp RH, Zhu X, Lau J, Waldeman J. Sex-hormone and lipid interactions: implications for cardiovascular disease in women. The Endocrinologist 1994; 4: 286-301.
32. Tikkanen MJ, Kuusi T, Nikkilä EA, Sipinen S. Post-menopausal hormone replacement therapy: effects of progesterone on serum lipids and lipoproteins, Maturitas 1986; 8: 1-17.
33. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its artherogenicity. N Engl J Med 1989; 320: 915-924.
34. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-2998.
35. Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GDO, Small M. Free radical activity and haemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992: 41: 909-913.
36. Gonen B, Baenziger J, Schonfeld G, Jacobsen D, Farrar P. Nonenzymatic glycosylation of low density lipoproteins in vitro. Diabetes 1981; 30: 875-878.
37. West KM, Ahuja MMS, Bennett PH, Czyzyk A, Mateo de Acosta O, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983; 6: 361-369.
38. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in eldery subjects. Diabetes 1994; 43: 960-967.
39. Andersson DKG, Svardsudd K. Long-term glycaemic control relates to mortality in type II diabetes. Diabetes Care 1995; 18: 1534-1543.
40. Sacks MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in post-menopausal women. Lancet 1994; 343: 269-270.
41. Wagner JD, St Clair RW, Schwenke DC, Shively CA, Adams MR, Clarkson TB. Regional differences in arterial low density lipoprotein metabolism in surgically post-menopausal cynomolgus monkeys. Arterioscl Thromb 1992; 12: 717-726.
42. McManus J, McEnemy J, Young I, Thompson W. Oestrogens reduce the susceptibility of LDL-cholesterol to oxidation. Maturitas: in press.
43. UKPDS Croup. United Kingdom Prospective Diabetes Study III. Prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes. Hypertension 1985; 7 (suppl 2): 8-13.
44. Bush TL, Barrett-Connor E. Non-contraceptive oestrogen use and cardiovascular disease. Epidemiol Rev 1985; 7: 81-104.
45. Perry I, Beevers M, Beevers DG, Leusley D. Oestrogens and cardiovascular disease (Letter). Br Med J 1988; 297: 1127.
46. Pfeffer RI, Kurosaki TT, Charlton SK. Oestrogen use and blood pressure in later life. Am J Epidemiol 1979; 110: 469-478.
47. Jespersen CM, Arnung K, Hagen C, Hilden T, Nielsen F, Damkjaer Nielsen M, et al. Effects of natural oestrogen therapy on blood pressure and renin-angiotensin system in normotensive and hypertensive menopausal women. J Hypertens 1983; 1: 361-364.
48. Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994; 8: 491-494.
49. Korsan-Bengtsen K, Wilhelmsen L, Elmfeldt D, Tibblin C. Blood coagulation and fibrinolysis in man after myocardial infarction compared with a representative population sample. Atherosclerosis 1972; 16: 83-88.
50. Walker ID, Davidson JF, Hutton I, Lawrie TDV. Disordered 'fibrinolytic potential' in coronary heart disease. Thromb Res 1977; 10: 509-520.
51. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
52. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994; 8 (suppl): 253-262.
53. Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetic Med 1991; 8: 898-905.
54. Nagi DK, Hendrie TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, et al. The relationships of concentrations of insulin, intact proinsulin and 32-33 split pro-insulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
55. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073.
56. van Wersch JW, Ubachs JM, van-de-Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in post-menopausal women. Eur J Clin Chem Clin Biochem 1994; 32: 449-453.
57. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal oestradiol and oral conjugated oestrogens on haemostatis variables. Thromb Haemost 1994; 71: 420-423.
58. Morise T, Takeuchi Y, Kawano M, Koni I, Taheda R. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995; 18: 87-89.
59. Chen JW, Gall M-A, Deckert M, Jensen JS, Parving H-H. Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy. Br Med J 1995; 311: 1406-1407.
60. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41 (suppl 2): 26-31.
61. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Olradia J. The effect of oestrogen replacement therapy on platelet aggregation and adenosine triphosphate release in post-menopausal women. Obstet Gynecol 1993; 81: 261-264.
62. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. Br Med J 1988; 297: 519-522.
63. Devot M, Barrett-Connor E, Renwall M, Feigal D, Ramsdell J. Oestrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-282.
64. Di Corleto PE, Soyombo A. The role of the endothelium in atherogenesis. Curr Opin Lipidol 1993; 4: 364-372.
65. Förstermann U, Mugge A, Alheid U, Haverich A, Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988; 62: 185-190.
66. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yueng AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491-497.
67. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989; 32: 219-226.
68. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHE, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323.
69. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736-741.
70. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, et al. Impaired endothelium-dependent and independent vasodilatation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
71. Pinkney JH, Denver AE, Mohamed-Ali V, Owens D, Foster C, Yudkin JS. Microalbuminuria in NIDDM: evidence for an association between insulin resistance and endothelial damage (Abstract). Diabetic Med 1995; 12 (suppl 1): S43.
72. Niskanen L, Laakso M. Insulin resistance is related to albuminuria in patients with type 2 (non-insulin dependent) diabetes mellitus. Metabolism 1993; 42: 1541-1545.
73. Stewart DJ, Monge JC. Hyperlipidemia and endothelial dysfunction. Curr Opin Lipidol 1993; 4: 319-324.
74. Tikkanen MJ. Mechanism of cardiovascular protection by postmenopausal hormone replacement therapy. Cardiovascular Risk Factors 1993; 3: 138-143.
75. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine induced coronary vasoreactivity. Am J Cardiol 1991; 68: 1425-1430.
76. Lehr HA, Krombach F, Münzing S, Bodlaj R, Glaubutt SI, Seiffge D, et al. In vitro effects of oxidised low density lipoprotein on CD11b/CD18 and L-selectin presentation on neutrophils and monocytes with relevance for the in vivo situation. Am J Path 1995; 146: 218-227.
77. Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple oxidation products in LDL induce IL-1β release from human blood mononuclear cells. J Lipid Res 1994; 35: 417-427.
78. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
79. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of oestrogen on coronary vasomotor function in post-menopausal women. Circulation 1994; 89: 2545-2551.
80. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Oestrogen improves endothelium-dependent flow mediated vasodilation in post-menopausal women. Ann Inter Med 1994; 121: 936-941.
81. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of oestrogen in postmenopausal women. Circulation 1994; 90: 786-791.
82. Sacks FM, Gerhard M, Walsh BM. Sex hormones, lipoproteins, and vascular reactivity. Curr Opin Lipidol 1995; 6: 161-166.
83. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA, Cardiovascular protection by oestrogen - a calcium antagonist effect? Lancet 1993; 341: 1264-1265.
84. Spagnoli LG, Palmieri G, Mauriello A, Orlandi A, Bancheri C, Pasetto N. High-dose synthetic progestogens inhibit foam and smooth muscle cell proliferation and atherosclerotic plaque formation in aortas of rabbits fed a hypercholesterolaemic diet. Atherosclerosis 1990; 82: 27-36.
85. Clarkson RB, Anthony MS, Klein KP. Effects of oestrogen treatment on arterial wall structure and function. Drugs 1994; 47 (suppl 2): 42-51.
86. Rigat B, Hubert C, Alhene-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin 1 converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
87. Keavney BD, Dudley CRK, Stratton IM, Holman RR, Matthews DR, Ratclifte PJ, et al. UK Prospective Diabetes Study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Diabetologia 1995; 38: 948-952.
88. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme in postmenopausal women. Lancet 1995; 346: 89-90.